ERCC1 rs11615 Single Nucleotide Polymorphism in Bladder Cancer Patients and Safety Outcomes of Cisplatin-Based Chemotherapy
Kotb, K., Soliman, M., Awadallah, A., Ahmed, A., Abol-Enein, H., Shams, M. (2024). ERCC1 rs11615 Single Nucleotide Polymorphism in Bladder Cancer Patients and Safety Outcomes of Cisplatin-Based Chemotherapy. EKB Journal Management System, 5(1), 42-48. doi: 10.21608/jampr.2024.271205.1063
Khaled M Kotb; Moetaza M Soliman; Amira Awadallah; Asmaa E Ahmed; Hassan Abol-Enein; Mohamed E E Shams. "ERCC1 rs11615 Single Nucleotide Polymorphism in Bladder Cancer Patients and Safety Outcomes of Cisplatin-Based Chemotherapy". EKB Journal Management System, 5, 1, 2024, 42-48. doi: 10.21608/jampr.2024.271205.1063
Kotb, K., Soliman, M., Awadallah, A., Ahmed, A., Abol-Enein, H., Shams, M. (2024). 'ERCC1 rs11615 Single Nucleotide Polymorphism in Bladder Cancer Patients and Safety Outcomes of Cisplatin-Based Chemotherapy', EKB Journal Management System, 5(1), pp. 42-48. doi: 10.21608/jampr.2024.271205.1063
Kotb, K., Soliman, M., Awadallah, A., Ahmed, A., Abol-Enein, H., Shams, M. ERCC1 rs11615 Single Nucleotide Polymorphism in Bladder Cancer Patients and Safety Outcomes of Cisplatin-Based Chemotherapy. EKB Journal Management System, 2024; 5(1): 42-48. doi: 10.21608/jampr.2024.271205.1063

ERCC1 rs11615 Single Nucleotide Polymorphism in Bladder Cancer Patients and Safety Outcomes of Cisplatin-Based Chemotherapy

Journal of Advanced Medical and Pharmaceutical Research
Volume 5, Issue 1, March 2024, Page 42-48  XML PDF (347.48 K)
Document Type: Original Article
DOI: 10.21608/jampr.2024.271205.1063
View on SCiNiTO View on SCiNiTO
Authors
Khaled M Kotb email 1; Moetaza M Solimanorcid 2; Amira Awadallah3; Asmaa E Ahmed4; Hassan Abol-Enein5; Mohamed E E Shams6
1Clinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt, 35516
2Clinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
3Center of excellence for Genome and Cancer Research, Urology and Nephrology Center, Mansoura University, Egypt
4Genetics Research Unit, Faculty of Medicine, Delta University for Science and Technology, Gamasa, Egypt
5Urology and Nephrology Center, Mansoura University, Mansoura, Egypt
6Clinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt
Abstract
This is a pilot single-center retrospective cohort research study aimed to investigate the relationship between single nucleotide polymorphism (SNP) of excision repair cross-complementation group 1 (ERCC1) rs11615 and the safety outcomes of cisplatin-based adjuvant chemotherapy in post-cystectomy bladder cancer patients. The study involved 25 patients with muscle invasive bladder cancer who were admitted to Urology and Nephrology Center (UNC), Mansoura University, Egypt between January and December 2016. The study tried to reveal the association between SNP rs11615 in ERCC1 gene and the change from baseline characteristics in a median of 96 weeks follow-up in blood, renal and hepatic biochemical parameters. Univariate analysis of the association between rs11615 and post-chemotherapy changes in uric acid and hemoglobin levels showed statistically significant relationship. These findings hint at possible genetic influences in response to chemotherapy, necessitating further research to understand the mechanisms and potential clinical implications. This could lead to personalized treatment plans enhancing patient care and outcomes.
Keywords
ERCC1; rs11615; Bladder Cancer; Chemotherapy; Safety Outcomes
Statistics
Article View: 55
PDF Download: 37